More Clinuvel Pharmaceuticals Limited news
Clinuvel Pharmaceuticals LimitedASX: CUV

S&P DJI Announces September 2022 Quarterly Rebalance

Sep 2, 2022 at 7:22 AM EDT · Issued by Clinuvel Pharmaceuticals Limited

Filed with ASX · Sep 2, 2022 at 7:22 AM EDT · 4 pages · English

On 6ix: 6ix.com/news/sandp-dji-announces-september-2022-quarterly-rebalance-34

Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27↗

Clinuvel Pharmaceuticals Limited on 6ix

Earlier from Clinuvel Pharmaceuticals

  • Appendix 4E and Annual Report 2022Aug 30, 2022
  • Positive Final Results in Stroke Study CUV801May 3, 2022
  • ACTH Manufacturing UpdateMar 16, 2022
  • afamelanotide in Stroke (AIS) - Positive Preliminary ResultsMar 14, 2022
  • CLINUVEL Reports December Half Year Operating ResultsFeb 22, 2022

Later from Clinuvel Pharmaceuticals

  • Quarterly Activities/Appendix 4C Cash Flow Report Re-issuedOct 30, 2022
  • Quarterly Activities/Appendix 4C Cash Flow ReportJan 30, 2023
  • Appendix 4E and Annual Report to Shareholders 2023Aug 29, 2023
  • CUV Appendix 4D Half Year ReportFeb 21, 2024
  • SCENESSE provides photoprotection in variegate porphyriaMar 3, 2024
All Clinuvel Pharmaceuticals news releases↗

Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.

Follow Clinuvel Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer